Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication

This open-label pilot trial (n=10) conducted by the University of British Columbia aims to assess the safety and feasibility of an 8-week psilocybin-assisted psychotherapy (25-37.5mg) intervention to facilitate tapering/discontinuation of opioid pain medication in adult patients with chronic pain.

Participants will undergo one or two psilocybin dosing sessions (25mg at week 3 and 37.5mg at week 7) alongside preparatory and integrative therapy sessions. The study will evaluate adverse events, dropout rates, and participant perceptions of the intervention’s benefits and harms.

Primary outcomes include feasibility, acceptability, and safety of psilocybin administration, while secondary outcomes involve changes in prescribed opioid dose over 1, 3, and 6-month follow-up periods.

The study commenced in November 2023 and is expected to conclude in August 2025.

Topic Pain
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of British Columbia


Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.